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www.jacctctabstracts2013.com MONDAY, OCTOBER 28, 2013, 8:00 AM–6:35 PMhemodynamic conditions. A saccular aneurysm without collateral branch will
thrombose quickly. If a collateral branch is present the ﬂow is directed towards this
branch leading to shrinkage of the aneurysm. Animal experiments show excellent
results. Moreover, as demonstrated in animal and human studies this MFM* preserves
the collateral branches allowing the possibility to cover any artery without compro-
mising the ﬂow (renal, digestive arteries, supra aortic vessels.)
Results: 40 peripheral An. (iliac:23, femoral:1, popliteal:5, renal:8, mesenteric:1,
carotid: 1, Subclavian : 1) were treated with the MFM* (male:31, mean age 62+/-8 y)
(52 stents Ø 5 to 14 mm; length 40 to 120 mm) were implanted to treat these aneu-
rysms, by femoral approach (39 cases), brachial approach (1 case), Technical success
in all patients. No complications. All An. thrombosed with diameter reduction in some
pts. The thrombosis could take several weeks depending on the importance of
collateral branches. 6 month to 36 month follow up will be presented and we will
discuss the time needed to achieve exclusion of the An. All the side branches remained
patent.
Conclusions: A new concept of stent, the MFM* (without any covering) is developed
to treat An. It opens a new approach to treat peripheral An. avoiding most of the
complications encountered with current endovascular techniques. The results obtained
seem promising. A larger study is ongoing.
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Background: Central sleep apnea (CSA), usually presenting as Hunter-Cheyne-
Stokes Breathing, occurs in approximately 35% of patients with heart failure. Current
treatment options for CSA have been limited and focus on mask based therapies and
therefore are highly dependent on tolerability and adherence. A novel therapy utilizing
phrenic nerve stimulation was developed using the remede System, a transvenous,
fully implantable system that is intended to restore a normal breathing pattern
throughout the night. This is the ﬁrst presentation of the study cohort with reduced
ejection fraction (EF) to evaluate of the remede System through 3 and 6 months.
Methods: Subjects received a remede System consisting of a respistimTM trans-
venous stimulation lead (in either the left pericardiophrenic or right brachiocephalic
vein) and a remede pulse generator which was placed in the pectoral area and secured
in a normal fashion. Thirty-ﬁve subjects with predominantly central sleep apnea were
enrolled. Subjects had an ejection fraction < 40% Subjects (age 659 years) and were
able to be evaluated at 3 and 6 months of therapy. 62% percent of subjects had
a concomitant cardiac device and 86% of subjects had chronic heart failure symptoms.
Standard PSG criteria were used for classiﬁcation of respiratory events and arousals.
Results: Both 3 and 6 month data demonstrate signiﬁcant improvements in apnea-
hypopnea index (AHI), central apnea index, oxygen desaturation index of 4%, arousal
index, REM sleep and sleep efﬁciency. In addition, there were signiﬁcant improve-
ments in quality of life at 6 months seen both in MLWHF (p¼0.0012) and NYHA
Classiﬁcation (p<0.0001).Changes in Respiratory and Symptoms with 6 months of remede System
Therapy
Parameter
Baseline
Mean +/-
Std Dev
3 Months
Mean +/-
Std Dev
6 Months
Mean +/- Std
Dev
Paired T-test
(Baseline to 6
Months
Apnea Hypopnea Index
(n/hr)
5115 2513 2413 <0.0001
Central Apnea Index
(n/hr)
3015 59 47 <0.0001
Oxygen Desaturation
Index 4% (n/hr)
4719 2413 2413 <0.0001
Arousal Index (n/hour) 3917 2611 2713 0.0002
Sleep Efﬁciency (%) 6818 7616 8013 0.0002
REM sleep (%) 106 168 186 <0.0001
MLWHFQ 3323 NA 2421 0.0012
Epworth Sleepiness
Scale
7.43.5 NA 4.72.9 <0.0001
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SConclusions: Treatment of CSA with the remede System signiﬁcantly improves
both respiratory and sleep parameters as well as symptoms of heart failure, in patients
with reduced EF. These favorable changes in pathophysiological consequences of
sleep apnea may lead to improvements in outcomes in patients with heart failure.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstracts/ORAL/25 Years oTCT-135
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Background: To describe the technique and proof the concept of a complete trans-
apical deployment of a single sidebranch arch endograft in a porcine model.
Methods: Eight domestic pigs were operated with antegrade transapical delivery of
a single-sidebranch arch endograft including a mating stentgraft to the innominate
artery. Technical feasibility, operating time, radiation parameters and hemody-
namic changes were studied according to standardized protocol during baseline
(T0), after establishing of the transapical access and through-and-through wire
(T1) and after stent-graft deployment (T2). Myocardial and cerebral perfusion
were assessed by ﬂuorescent-microspheres (FM) and transit-time-ﬂow measure-
ment (TTFM).
Results: Transapical access, introduction and deployment of the endograft, side-
branch catheterization and deployment of the mating stent-graft were feasible in 6 of
the 8 animals with unimpeded perfusion of the innominate artery. One animal was lost
during transapical access, one during sire-branch catheterization. The mean operating
and ﬂuoroscopy times were 15747min and 15.93.2min. During introduction and
deployment of the stent-graft transient aortic valve insufﬁciency occurred in all
animals. Hemodynamic stability recovered within ten minutes after retrieval of the
delivery system in all animals. The innominate artery was patent with unchanged
TTFM-ﬂow measurements throughout the procedure. FM evaluation revealed stable
myocardial and cerebral perfusion.
Conclusions: Antegrade transapical access to the aortic arch for implantation of
a single sidebranch arch endograft is feasible in a porcine model with reversible
impact on hemodynamic measures during deployment. Transapical access allows for
deployment of a complex endograft through a single large bore access-site in a porcine
model. It might be a future treatment option for selective patients.
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Background: Diastolic dysfunction develops in most cardiac conditions, and leads to
elevation of left ventricular ﬁlling pressures and heart failure. We report the initial
experience with a novel device intended to lower left atrial pressure by creating
a small permanent atrial septal shunt. The objective of the study was to evaluate safety
and potential beneﬁts of the Intra Atrial Shunt Device (IASD) System in patients
with symptomatic heart failure with preserved or mildly reduced ejection fraction,
despite appropriate medical management.
Methods: The ﬁrst 6 patients in a prospective multicenter feasibility study were
enrolled under an approved protocol. Key inclusion criteria were: EF > 45%; PCWP
at rest  15 or exercise  25mm Hg; or  1 hospitalization for heart failure within
prior 12 months; or persistent NYHA Class III/IV for at least 3 months.
Results: Mean age, EF, and NYHA Class were 75 Y, 57 %, and III, respectively.
Most patients had multiple comorbidities. The IASD Device was successfully
implanted in each patient using standard interventional techniques and guidance. One
SAE (complete heart block) occurred within 30 days, and resolved (pacemaker). The
SAE was not related to the procedure or device. At 30 days, PCWP was reduced, and
at 30 days clinical symptoms had improved in 5 of 6 patients. Additional follow-up
data will be presented.f Interventional Innovation: Novel Therapies and the “Emerging” Device Concepts for 2013 B43
